Schedule 13G ownership disclosure

Entrada Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 29384C108

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Roche Finance Ltd

    Shares: 2,569,115.00 · Class: 6.9%

  • Roche Holding Ltd

    Shares: 2,569,115.00 · Class: 6.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-014005
Form type
SCHEDULE 13G/A
Filer
Entrada Therapeutics, Inc.
CIK
CIK 1689375
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub